Clinical Trials for Mesothelioma

Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced, metastatic, or recurrent mesothelioma (epithelioid or biphasic with >80% epithelioid), or other solid tumors with high mesothelin expression (≥50% of tumor cells), who have progressed after standard therapies. Treatment involves lymphodepleting chemotherapy followed by a single infusion of autologous CAR T cells (TNhYP218) engineered to target a membrane-proximal epitope of mesothelin, using naive/stem cell memory T cells to potentially enhance efficacy.

ClinicalTrials.gov ID: NCT06885697

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

TrialFetch AI summary: Enrolling adults with advanced/metastatic solid tumors lacking standard options; dose-escalation all-comers followed by expansion in biomarker-selected cohorts including NSCLC with YES1 or TYMS amplification or FAT1 mutation, renal cancer or mesothelioma with NF2 mutation, and other tumors with NF2/FAT1/LATS1 mutations or TYMS/YAP1/YES1/TAZ1 amplifications. Treatment is NXP900, an oral conformation-selective SRC family kinase inhibitor with high potency against YES1/SRC, given as monotherapy.

ClinicalTrials.gov ID: NCT05873686

A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers

TrialFetch AI summary: Adults with advanced, unresectable or metastatic solid tumors across multiple cohorts (e.g., gastric/EGJ, colorectal, pancreatic, sarcoma, mesothelioma, neuroendocrine, cutaneous/anal SCC, Merkel cell, MMR‑deficient/MSI cancers) after standard therapy, ECOG 0–1; stable small brain mets allowed. Treatment is autologous tumor-infiltrating lymphocyte (TIL) therapy (tumor harvest → ex vivo expansion) after cyclophosphamide/fludarabine lymphodepletion, followed by high-dose aldesleukin (IL-2) to support T-cell expansion; single course with option for a second.

ClinicalTrials.gov ID: NCT03935893

Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression

TrialFetch AI summary: Adults with mesothelin-expressing advanced solid tumors (ECOG 0–1) receive weekly IV CT-95 (LNK-101), a mesothelin × CD3 T‑cell–engaging bispecific antibody engineered for reduced off‑tumor activation, in a dose-escalation/expansion study. Excludes prior mesothelin-targeted CD3/CAR‑T therapy; evaluates safety, PK, and preliminary efficacy across tumor types including mesothelioma.

ClinicalTrials.gov ID: NCT06756035

Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced mesothelioma or solid tumors harboring Hippo pathway dysregulation (e.g., NF2 loss or YAP/TAZ alterations), ECOG 0–1, receive the oral TEAD inhibitor VT3989 (blocks TEAD autopalmitoylation to inhibit YAP/TAZ–TEAD signaling) as monotherapy or in combination. Combination cohorts include treatment-naïve unresectable/metastatic mesothelioma with nivolumab/ipilimumab and EGFR-mutant NSCLC (ex19del/L858R) with osimertinib; key exclusions include active CNS disease and prior TEAD inhibitors.

ClinicalTrials.gov ID: NCT04665206

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)

TrialFetch AI summary: Adults with unresectable pleural mesothelioma (epithelioid or non-epithelioid), ECOG 0–1, are randomized to volrustomig (a bispecific PD-1/CTLA-4 antibody) plus carboplatin/pemetrexed versus investigator’s choice of platinum/pemetrexed (epithelioid) or nivolumab plus ipilimumab (either histology; standard for non-epithelioid). Key exclusions include significant autoimmune disease and uncontrolled infections; primary endpoint is overall survival.

ClinicalTrials.gov ID: NCT06097728

A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma

TrialFetch AI summary: Adults with mesothelin-expressing recurrent/relapsed advanced ovarian (including primary peritoneal/fallopian tube), cholangiocarcinoma, or epithelial mesothelioma (pleural/peritoneal), ECOG 0–1, after ≥1 prior therapy, receive lymphodepleting chemotherapy followed by a single infusion of SynKIR-110, an autologous T-cell therapy using a mesothelin-targeted KIR-CAR (activating KIR plus DAP12) designed to enhance persistence/function in solid tumors. Excludes prior gene-engineered T-cell therapy, sarcomatoid/biphasic mesothelioma, active viral infections, significant pulmonary disease, and active autoimmune disease.

ClinicalTrials.gov ID: NCT05568680

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors

TrialFetch AI summary: Adults with advanced solid tumors; dose escalation includes refractory/metastatic tumors (notably malignant mesothelioma and epithelioid hemangioendothelioma), with expansion for mesothelioma, EHE regardless of Hippo status, and other tumors harboring Hippo pathway alterations. Patients receive oral BGC515, a covalent pan‑TEAD1–4 inhibitor targeting the Hippo/YAP–TAZ transcriptional pathway, once daily in 21‑day cycles.

ClinicalTrials.gov ID: NCT06452160

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

TrialFetch AI summary: Enrolling adults with advanced solid tumors or lymphomas, including molecularly defined cohorts such as ARID1A-mutant endometrial/ovarian clear cell and other solid tumors, BAP1-loss mesothelioma, PTCL/DLBCL (including EZH2-mutant), and mCRPC. Investigational therapy is tulmimetostat (CPI-0209), an oral dual EZH2/EZH1 inhibitor, given as monotherapy across cohorts and combined with enzalutamide in mCRPC.

ClinicalTrials.gov ID: NCT04104776

Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma

TrialFetch AI summary: Adults with HRD-positive malignant mesothelioma (pleural, peritoneal, or tunica vaginalis) who are platinum-sensitive after prior cisplatin/carboplatin, ECOG 0–1, receive single-agent olaparib. Olaparib is an oral PARP1/2 inhibitor leveraging synthetic lethality in BAP1/HRR-deficient tumors; excludes prior PARP use and platinum-resistant disease.

ClinicalTrials.gov ID: NCT04515836